

Cardiovascular Off-Cycle Review: Measure Evaluation Recusals

The <u>NQF CDP Conflict of Interest Policy</u> requires that Committee members identified as having a potential conflict of interest in relation to specific measures must recuse themselves from evaluation and voting on those measures when seated on the Committee.

In the review of disclosure of interests submitted by Committee members, NQF is requiring the following recusals be made during the measure evaluation period.

Measures Under Review & Committee Member Recusals

Measure	Measure Title	Measure	Committee Member Recusals
Number		Steward	
#2764	Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy	NMQF	Gary Puckrein, PhD, President, National Minority Quality Forum